Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.
Diagonal Therapeutics has raised $125.0M in total funding. The most recent round was Series B. The last funding was announced in January 2026.
Diagonal Therapeutics's investors include Lightspeed Venture Partners, RA Capital Management, Janus Henderson Investors, Frazier Life Sciences, EcoR1 Capital.
Diagonal Therapeutics is headquartered in Watertown, United States.
Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.
Diagonal Therapeutics is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Diagonal Therapeutics — Funding & Investors." VCBacked, January 8, 2026, https://www.vcbacked.co/company/diagonal-therapeutics. Accessed July 19, 2026.
VCBacked. (2026). Diagonal Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/diagonal-therapeutics
{{cite web |title=Diagonal Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/diagonal-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated